Poland· PL-100506266
Ituxredi
A rituximab product containing rituximabum, registered in Poland by Reddy Holding GmbH. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rituximab is registered in 3 of 19 countries.
Countries holding a registration under ATC L01XC02 (rituximab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 2 of them publish a price we can compare per daily dose
Rituximab · ATC L01XC02
3 / 19 countries
- Belgiumprice
- Ireland
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Rituximabum
- Manufacturer
- Reddy Holding GmbH
- Country
- Poland (PL)
- ATC code
- L01XC02
- ATC class
- Rituximab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for rituximab.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rituximab · interactions on record
81 records
- 32 severe
- 42 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rituximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandBlitzimaCelltrion Healthcare Hungary Kft.
- CzechiaBLITZIMACelltrion Healthcare Hungary Kft., Budapest
- BelgiumBlitzima 100 mgCelltrion Healthcare Hungary
- SwedenBlitzima 100 mg Koncentrat till infusionsvätska, lösningCelltrion Healthcare Hungary Kft
- IcelandBlitzimaCelltrion Healthcare Hungary Kft.
- IrelandBlitzima 100 mg concentrate for solution for infusionCelltrion Healthcare Hungary Kft.
- United KingdomItuxredi 100mg/10ml concentrate for solution for infusion vialsDr Reddy's Laboratories (UK) Ltd
- NetherlandsBlitzima 100 mg, concentraat voor oplossing voor infusieCelltrion Healthcare Hungary Kft.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ituxredi
- Iceland · Blitzima, Mabthera
- Liechtenstein · Blitzima, Mabthera
- Norway · Blitzima, Mabthera
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b590d159-b6b4-4423-b72b-6aad0486a85f GET /v1/drugs/b590d159-b6b4-4423-b72b-6aad0486a85f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "100 mg",
"packaging": "Rpz ¦ EU/1/24/1861/001 ¦ 158321\n1 fiol. \nRpz ¦ EU/1/24/1861/002 ¦ 158322\n2 fiol.",
"substance": "Rituximabum 100 mg",
"common_name": "Rituximabum",
"pl_product_id": "100506266",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about rituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.